肠道微生态与非酒精性脂肪性肝病的相关性研究现状及临床意义

Relationship between gut microbiota and non-alcoholic fatty liver disease

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的发病率近年来不断提高,而随着对肠道微生态认知的加深,二者的关系逐渐明确.动物和临床实验均指出肠道菌群可通过肠-肝轴和二次打击机制促使NAFLD的发生,并在肝炎症反应和纤维化中发挥重要作用.通过益生菌、益生元和小檗碱及抗生素等方式调节肠道菌群可减轻患者的肝病程度,并可调节体质量指数,减轻胰岛素抵抗,是治疗NAFLD等代谢性疾病的新思路.

The incidence of non-alcoholic fatty liverdisease （NAFLD） has been increasing during these years. As we understand more about gut microbiota, the relationship between gut microbiota and NAFLD has been revealed. Both animal experiments and clinical studies show that gut microbiota can not only act on NAFLD via the gut-liver axis and two- hit theory, but also play an important role in liver inflammation and hepatic fibrosis. Experiments also indicate that using probiotics, prebiotics, berberine and antibiotics to regulate gut microbiota can relieve inflammation, lower body mass index and improve insulin resistance, which can be a new treatment for NAFLD and other metabolic diseases.